Amgen Fremont Inc.

Pfizer Corporation

Amgen Inc.

Abgenix, Inc.

Other

C Geoffrey Davis

Jose Corvalan

Douglas Charles Hanson

Eileen Elliott Mueller

Steven Christopher Gilman

Jeffrey Herbert Hanke

Mark Joseph Neveu

William James Boyle

Francis Hall Martin

Larry L Green

Vladimir E Ivanov

Jose Ramon Corvalan

Eileen Elliot Mueller

José Ramon Corvalan

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

Human monoclonal antibodies to CTLA-4

Methods of treating cancer with human monoclonal antibodies to CTLA-4

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

Methods for treating bone loss with antibodies to OPGL

Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.

Polynucleotides encoding heavy and light chains of antibodies to OPGL

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

Nucleic acids encoding human monoclonal antibodies to CTLA-4

Antibodies to OPGL

Methods and host cells for producing human monoclonal antibodies to CTLA-4

Methods for expressing and recovering human monoclonal antibodies to CTLA-4

The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i.e., a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i.e., a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment. The switch region and membrane exons of the invention may comprise a human gamma-2 constant region and the secreted constant region exons are from a human gamma-1 or a human gamma-4 constant region.

Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions

Growing community of inventors

Burlingame, CA, United States of America

C Geoffrey Davis